drugset

drugset / Trial / NCT06996912

A Study for HSK44459 in Participants With Atopic Dermatitis

NCT06996912 ↗

Phase 2 Active not recruiting 150 enrolled Xizang Haisco Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis

Timeline

Start: 2025-05-22
Primary completion: 2026-01-20
Completion: 2026-03-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK44459	Unknown	—	Oral

Indications